BMC Womens Health. 2022 Jan 15;22(1):14. doi: 10.1186/s12905-022-01596-2.

Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.

BMC women's health

Juliawati Muhammad, Yusnita Yusof, Imran Ahmad, Mohd Noor Norhayati

PMID: 35033041 DOI: 10.1186/s12905-022-01596-2

Abstract

BACKGROUND: Elagolix is effective and safe for treating menorrhagia in women with uterine fibroid. However, it is reported to be associated with hypoestrogenism that can be alleviated by adding estradiol/norethindrone acetate. This systematic review and meta-analysis aimed to determine the effectiveness of elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid by comparing: elagolix versus placebo and elagolix versus estradiol/norethindrone acetate.

METHODOLOGY: The Cochrane Central Register of Controlled Trials (CENTRAL 2021, Issue 3 of 12), MEDLINE databases (1980 to December week 1, 2020), and trial registries for relevant randomized clinical trials were used. All randomized clinical trials were reviewed and evaluated. Random effects models were used to estimate the dichotomous outcomes and mean differences with 95% confidence intervals. Data for risk of bias, heterogeneity, sensitivity, reporting bias and quality of evidence were assessed.

RESULTS: Four randomized controlled trials with 1949 premenopausal women from 323 locations were included. Elagolix improved menstrual blood loss of less than 80 ml (RR 4.81, 95% CI 2.45 to 9.45; four trials, 869 participants; moderate quality evidence) or more than 50% reduction from baseline (RR 4.87, 95% CI 2.55 to 9.31; four trials, 869 participants; moderate quality evidence) compared to placebo. There was no difference in menstrual blood loss of less than 80 ml (RR 1.08, 95% CI 1.00 to 1.16; five trials, 1365 participants; moderate quality evidence) or more than 50% reduction from baseline between the elagolix (RR 1.08, 95% CI 1.01 to 1.15; five trials, 1365 participants; high quality evidence) and elagolix with estradiol/norethindrone acetate. In both comparisons, elagolix has reduced the mean percentage change in uterine and fibroid volume, improved symptoms, and health-related quality of life. More patients had hot flush, and bone mineral density loss in the elagolix treatment compared to both placebo and elagolix with estradiol/norethindrone acetate.

CONCLUSIONS: Elagolix appeared to be effective in reducing heavy menstrual bleeding caused by uterine fibroid and combination with estradiol/norethindrone acetate was able to alleviate the hypoestrogenism side effects in premenopausal women. Review registration PROSPERO CDR 42021233898.

© 2022. The Author(s).

Keywords: Elagolix; Estradiol/norethindrone acetate; GnRH antagonist; Heavy menstrual bleeding; Leiomyoma; Uterine fibroid

References

1. Fleischer R, Weston GC, Vollenhoven BJ, Rogers PAW. Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):603–14. - PubMed
2. Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293–8. - PubMed
3. Neri M, Melis GB, Giancane E, Vallerino V, Pilloni M, Piras B, et al. Clinical utility of elagolix as an oral treatment for women with uterine fibroids: A short report on the emerging efficacy data. Int J Women’s Health. 2019;11:535–46. - PubMed
4. Sabry M, Al-Hendy A. Medical treatment of uterine leiomyoma. Reprod Sci. 2012;19(4):339–53. - PubMed
5. Marsh EE, Al-Hendy A, Kappus D, Galitsky A, Stewart EA, Kerolous M. Burden, prevalence, and treatment of uterine fibroids: A Survey of U. S. Women. J Women’s Health. 2018;27(11):1359–67. - PubMed
6. Fuldeore MJ, Soliman AM. Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis. Int J Women’s Health. 2017;9:403–11. - PubMed
7. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990;94(4):435–8. - PubMed
8. Nowak RA. Fibroids: pathophysiology and current medical treatment. Best Pract Res Clin Obstet Gynaecol. 1999;13(2):223–38. - PubMed
9. ElKafas H, Ali M, Al-Hendy A. Leiomyomas. In: Skinner MK, editor. Encyclopedia of reproduction. 2nd ed. Oxford: Academic Press; 2018. p. 101–5. - PubMed
10. Fantasia HC. Elagolix as a novel treatment for endometriosis-related pain. Nurs Womens Health. 2019;23(4):366–9. - PubMed
11. Barra F, Vitale SG, Seca M, Scala C, Leone Roberti Maggiore U, Cianci A, et al. The potential role of elagolix for treating uterine bleeding associated to uterine myomas. Expert Opin Pharmacother. 2020;21(12):1419–30. - PubMed
12. Finch AR, Caunt CJ, Armstrong SP, McArdle CA. Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors. Am J Physiol Cell Physiol. 2009;297(3):C591–600. - PubMed
13. Griesinger G, Felberbaum R, Diedrich K. GnRH-antagonists in reproductive medicine. Arch Gynecol Obstet. 2005;273(2):71–8. - PubMed
14. Nader A, Mostafa NM, Ali F, Shebley M. Drug-drug interaction studies of elagolix with oral and transdermal low-dose hormonal add-back therapy. Clin Pharmacokinet. 2020;60:133. - PubMed
15. Hallberg L, Hôgdahl A-M, Nilsson L, Rybo G. Menstrual blood loss–a population study. Acta Obstet Gynecol Scand. 1966;45(3):320–51. - PubMed
16. Mawet M, Nollevaux F, Nizet D, Wijzen F, Gordenne V, Tasev N, et al. Impact of a new levonorgestrel intrauterine system, Levosert®, on heavy menstrual bleeding: results of a one-year randomised controlled trial. Eur J Contracept Reprod Health Care. 2014;19(3):169–79. - PubMed
17. Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004;190(5):1216–23. - PubMed
18. Fraser IS, Warner P, Marantos PA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume1 1We acknowledge the substantial contributions of Gay McCarron, Tanya Resta, and Robert Markham to the execution of this study. Obstet Gynecol. 2001;98(5, Part 1):806–14. - PubMed
19. Higgins JP, Deeks JJ, Altman DG, Group obotCSM. Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions 2019. p. 241–84. - PubMed
20. RevMan. Review Manager (Computer program) Version 5.4 The Cochrane Collaboration 2020 [ - PubMed
21. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6. - PubMed
22. Kim JH, Al-Hendy A, Archer DF, Barnhart K, Bradley LD, Feinberg E, et al. Clinical outcomes in elagolix-treated women with uterine fibroids who did not meet the study endpoint criteria in two phase 3 trials. J Minimally Invasive Gynecol. 2020;27(7, Supplement):S49. - PubMed
23. Al-Hendy A, Bradley L, Owens CD, Wang H, Barnhart KT, Feinberg E, et al. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. Am J Obst Gynecol. 2020. - PubMed
24. Polepally AR, Ng JW, Salem AH, Dufek MB, Parikh A, Carter DC, et al. Assessment of clinical drug-drug interactions of elagolix, a gonadotropin-releasing hormone receptor antagonist. J Clin Pharmacol. 2020;60(12):1606–16. - PubMed
25. Muneyyirci-Delale O, Archer DF, Jeannie Kim JH, Liu R, Owens CD, Puscheck EE. Phase 3 trial results: efficacy and safety of elagolix in a subset of women with uterine fibroids and adenomyosis. Fertility sterility. 2019;112(3):e4. - PubMed
26. Taylor HS, Bedaiwy MA, Lukes AS, Chwalisz K, Owens C, Bradley L. Efficacy and safety of elagolix in a subgroup of women with uterine fibroids and adenomyosis: results from a phase 2 trial. Fertility Sterility. 2018;110(4, Supplement):e61. - PubMed
27. Archer DF, Stewart EA, Jain RI, Feldman RA, Lukes AS, North JD, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril. 2017;108(1):152-60.e4. - PubMed
28. Carr BR, Stewart EA, Archer DF, Al-Hendy A, Bradley L, Watts NB, et al. Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2018;132(5):1252–64. - PubMed
29. Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328–40. - PubMed
30. Simon JA, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, Carr BR, et al. Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas. Obstet Gynecol. 2020;135(6):1313–26. - PubMed
31. Mansfield PK, Voda A, Allison G. Validating a pencil-and-paper measure of perimenopausal menstrual blood loss. Womens Health Issues. 2004;14(6):242–7. - PubMed

Publication Types

• Journal Article